202 related articles for article (PubMed ID: 23121978)
21. Frequency and expression of inhibitory markers of CD4(+) CD25(+) FOXP3(+) regulatory T cells in patients with common variable immunodeficiency.
Arandi N; Mirshafiey A; Abolhassani H; Jeddi-Tehrani M; Edalat R; Sadeghi B; Shaghaghi M; Aghamohammadi A
Scand J Immunol; 2013 May; 77(5):405-12. PubMed ID: 23432692
[TBL] [Abstract][Full Text] [Related]
22. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Gautron AS; Dominguez-Villar M; de Marcken M; Hafler DA
Eur J Immunol; 2014 Sep; 44(9):2703-2711. PubMed ID: 24838857
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
24. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
25. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Sakuishi K; Apetoh L; Sullivan JM; Blazar BR; Kuchroo VK; Anderson AC
J Exp Med; 2010 Sep; 207(10):2187-94. PubMed ID: 20819927
[TBL] [Abstract][Full Text] [Related]
26. Functional exhaustion of CD4
Ozkazanc D; Yoyen-Ermis D; Tavukcuoglu E; Buyukasik Y; Esendagli G
Immunology; 2016 Dec; 149(4):460-471. PubMed ID: 27565576
[TBL] [Abstract][Full Text] [Related]
27. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
28. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease.
Wong M; La Cava A; Hahn BH
J Immunol; 2013 Jun; 190(11):5402-10. PubMed ID: 23636058
[TBL] [Abstract][Full Text] [Related]
29. Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10.
Bedke T; Pretsch L; Karakhanova S; Enk AH; Mahnke K
J Immunol; 2010 May; 184(10):5562-70. PubMed ID: 20382886
[TBL] [Abstract][Full Text] [Related]
30. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Woo SR; Turnis ME; Goldberg MV; Bankoti J; Selby M; Nirschl CJ; Bettini ML; Gravano DM; Vogel P; Liu CL; Tangsombatvisit S; Grosso JF; Netto G; Smeltzer MP; Chaux A; Utz PJ; Workman CJ; Pardoll DM; Korman AJ; Drake CG; Vignali DA
Cancer Res; 2012 Feb; 72(4):917-27. PubMed ID: 22186141
[TBL] [Abstract][Full Text] [Related]
31. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
32. Pillars Article: An Essential Role for Scurfin in CD4+CD25+ T Regulatory Cells. Nat. Immunol. 2003. 4: 337-342.
Khattri R; Cox T; Yasayko SA; Ramsdell F
J Immunol; 2017 Feb; 198(3):993-998. PubMed ID: 28115588
[No Abstract] [Full Text] [Related]
33. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
34. Application of cultured human regulatory T cells requires preclinical in vivo evaluation.
Vercoulen Y; Guichelaar T; Meerding J; Emmelot M; Pingen M; Storm G; Coffer P; Sawitzki B; Martens A; Mutis T; Prakken B
J Allergy Clin Immunol; 2012 Mar; 129(3):852-855.e3. PubMed ID: 22168999
[No Abstract] [Full Text] [Related]
35. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.
Goding SR; Wilson KA; Xie Y; Harris KM; Baxi A; Akpinarli A; Fulton A; Tamada K; Strome SE; Antony PA
J Immunol; 2013 May; 190(9):4899-909. PubMed ID: 23536636
[TBL] [Abstract][Full Text] [Related]
36. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Paterson AM; Lovitch SB; Sage PT; Juneja VR; Lee Y; Trombley JD; Arancibia-Cárcamo CV; Sobel RA; Rudensky AY; Kuchroo VK; Freeman GJ; Sharpe AH
J Exp Med; 2015 Sep; 212(10):1603-21. PubMed ID: 26371185
[TBL] [Abstract][Full Text] [Related]
37. Foxp3
Kohno M; Murakami J; Wu L; Chan ML; Yun Z; Cho BCJ; de Perrot M
J Immunol; 2020 Nov; 205(9):2519-2531. PubMed ID: 32948683
[TBL] [Abstract][Full Text] [Related]
38. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
39. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
Shokrgozar N; Karimi M; Golmoghaddam H; Rezaei N; Moayed V; Sharifzadeh S; Arandi N
Ann Hematol; 2021 Oct; 100(10):2463-2469. PubMed ID: 34324022
[TBL] [Abstract][Full Text] [Related]
40. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
